Literature DB >> 22024529

Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.

Steve Innes1, Jennifer Norman, Pete Smith, Marlize Smuts, Edmund Capparelli, Bernd Rosenkranz, Mark Cotton.   

Abstract

BACKGROUND: Stavudine, a nucleoside reverse transcriptase inhibitor, is used commonly to treat HIV-infected children in the developing world. The paediatric liquid formulation presents major logistical difficulties in rural and resource-limited areas, and prescribers are frequently forced to employ off-label 'opened capsule' dosing methods using the adult capsule. The South African Department of Health (DoH) has advised that caregivers should be instructed to disperse the contents of an adult capsule in 5 ml water and then withdraw the required dose using a syringe. The bioavailability of stavudine using the opened capsule dosing method has not previously been validated.
METHODS: This was a randomized crossover pharmacokinetic study with each subject serving as his/her own control. A total of 28 healthy HIV-negative adult volunteers were randomized on a 1:1 basis to receive one of the two generic preparations typically available in state hospitals. They were then further randomized to receive either intact or opened 30 mg capsules. After 1 week, those who initially received intact capsules, were given opened capsules and vice versa. The capsule dispersion technique used was identical to that prescribed by the DoH. Serial blood samples were collected and plasma stavudine concentrations were assayed by liquid chromatography tandem mass spectrometry. Stavudine pharmacokinetics were analysed using non-compartmental methods and formulations were compared using ANOVA.
RESULTS: Plasma drug exposure after stavudine administration as a solution using an opened capsule dosing method was found to be bioequivalent to intact capsule administration. This was true for both generics tested.
CONCLUSIONS: The opened capsule dosing technique is bioequivalent to intact capsule dosing for stavudine in HIV-seronegative adults.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024529      PMCID: PMC5054241          DOI: 10.3851/IMP1876

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  3 in total

1.  Bioavailability of a pediatric amlodipine suspension.

Authors:  Dorothy A Lyszkiewicz; Zina Levichek; Eran Kozer; Yaron Yagev; Myla Moretti; Marjie Hard; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2003-05-07       Impact factor: 3.714

2.  Comparative study of different brands of stavudine capsules for the off-label 'opened capsule' dosing method recommended for HIV-infected infants and children in resource-limited settings.

Authors:  Steve Innes; Marlize Smuts; Mark F Cotton; Heiner Seifart; Bernd Rosenkranz
Journal:  SAJCH       Date:  2009-07

3.  The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule.

Authors:  Susan M Abdel-Rahman; Franklin K Johnson; Ginette Gauthier-Dubois; Irving E Weston; Gregory L Kearns
Journal:  J Clin Pharmacol       Date:  2003-02       Impact factor: 3.126

  3 in total
  6 in total

Review 1.  Formulations for children: problems and solutions.

Authors:  Hannah K Batchelor; John F Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

2.  Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

Authors:  Sherwin K B Sy; Ruben Malmberg; Aoi Matsushima; Eduardo Asin-Prieto; Bernd Rosenkranz; Mark F Cotton; Hartmut Derendorf; Steve Innes
Journal:  Int J Antimicrob Agents       Date:  2015-01-19       Impact factor: 5.283

3.  Third-Line Antiretroviral Therapy: What Do We Do When the Appropriate Formulations Are Not Available?

Authors:  Lisa Jane Frigati; Helena Rabie
Journal:  Children (Basel)       Date:  2022-03-30

4.  Estimation of intracellular concentration of stavudine triphosphate in HIV-infected children given a reduced dose of 0.5 milligrams per kilogram twice daily.

Authors:  Sherwin K B Sy; Steve Innes; Hartmut Derendorf; Mark F Cotton; Bernd Rosenkranz
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

5.  Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir.

Authors:  J P Routy; J B Angel; J N Spaans; B Trottier; D Rouleau; J G Baril; M Harris; S Trottier; J Singer; N Chomont; R P Sékaly; C L Tremblay
Journal:  HIV Clin Trials       Date:  2012 Nov-Dec

6.  Antiretroviral therapy during the neonatal period.

Authors:  James J C Nuttall
Journal:  South Afr J HIV Med       Date:  2015-05-04       Impact factor: 2.744

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.